Loading...
•
Sep 30, 2024
Inovio Q3 2024 Earnings Report
INOVIO reported its financial results for the third quarter of 2024 and provided an update on recent company developments.
Key Takeaways
INOVIO's primary focus is driving toward the regulatory approval and commercialization of its lead product candidate, INO-3107. The company is preparing regulatory submissions for INO-3107 and expects to have all non-device BLA modules completed by the end of 2024, with BLA submission targeted for mid-2025.
Continued progress on preparing regulatory submissions for INO-3107, with all non-device BLA modules on track for completion by end of 2024 and BLA submission targeted for mid-2025.
Presented new immunology data supporting INO-3107's mechanism of action, showing its ability to induce antigen-specific cytotoxic T cell response against HPV-6 and HPV-11.
Presented full safety and efficacy data for INO-3107's Phase 1/2 trial, demonstrating it was well tolerated and had clinical benefit, with 81% of patients experiencing a decrease in surgical interventions.
Advanced plans for a Phase 3 trial of INO-3112 for HPV-related oropharyngeal squamous cell carcinoma and a Phase 2 trial of INO-4201 as a heterologous boost to the FDA licensed Ebola vaccine.
Forward Guidance
INOVIO estimates its cash runway to extend into the third quarter of 2025, which includes an operational net cash burn estimate of approximately $24 million for the fourth quarter of 2024. These projections do not include any further capital-raising activities that INOVIO may undertake.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...